Mayo Clinic, iSpecimen Collaboration
News Sep 13, 2016
iSpecimen® announced that it has entered into an agreement with the Mayo Clinic Center for Individualized Medicine. Under the agreement, iSpecimen will serve as the exclusive channel partner for the Mayo Clinic Cancer/Normal Serum Biobank, connecting biomedical researchers with the samples and associated data for their studies.
The Cancer/Normal Serum Biobank, located on Mayo Clinic’s campus in Rochester, Minnesota, includes approximately 130,000 frozen vials of serum from about 17,000 unique, consented patients. The samples were collected between 1975 and 1990 across 85 different malignant and benign conditions. iSpecimen, which works to procure annotated samples for life science researchers, will manage the serum inventory and associated data through its cloud-based technology solution, matching researchers to the right samples to fuel their studies.
“As is the case with many biorepositories, intensive resources have been put into creating a variety of sample collections along with state-of-the-art facilities,” said Stephen Thibodeau, Ph.D., the David F. and Margaret T. Grohne Director, Biorepositories Program, Mayo Clinic Center for Individualized Medicine. “But despite holding thousands of sought-after samples, the biorepository is underutilized by external researchers. iSpecimen presented an opportunity for us to work with them to efficiently move these specimens into the hands of many more scientists studying cancer and related conditions, which ultimately should result in better treatments.”
With the surge of precision medicine, and particularly increased interest and funding for cancer research, as evidenced by initiatives such as the Cancer Moonshot and Parker Institute for Cancer Immunotherapy, Mayo Clinic’s Cancer/Normal Serum Biobank presents research value not only due to the thousands of serum samples it holds, but also due to the longitudinal nature of many of the samples. Also of considerable value is the clinical annotation accompanying the samples; this includes patient demographics, blood collection data, tumor information, treatment information, and status of tumor at time of blood collection.
“Developed specifically with researchers in mind, iSpecimen is proud to collaborate with Mayo Clinic to help to expand this biobank’s reach across the scientific community,” said Christopher Ianelli, M.D., Ph.D., Chief Executive Officer, iSpecimen. “It’s estimated that the number of new cancer cases per year will rise from 14 to 22 million globally within the next two decades. As oncology research continues to evolve at a rapid pace, providing researchers fast access to the right, high-quality biospecimens will be crucial to helping them execute on new ways of understanding, diagnosing and treating this disease.”
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019